- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-5551
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression ; volume:35 ; number:1 ; day:24 ; month:3 ; year:2020 ; pages:75-89 ; date:1.2021
Leukemia ; 35, Heft 1 (24.3.2020), 75-89, 1.2021
- Creator
-
Fousek, Kristen
Watanabe, Junji
Joseph, Sujith K.
George, Ann
An, Xingyue
Byrd, Tiara T.
Morris, Jessica S.
Luong, Annie
Martínez-Paniagua, Melisa A.
Sanber, Khaled
Navai, Shoba A.
Gad, Ahmed Z.
Salsman, Vita S.
Mathew, Pretty R.
Kim, Hye Na
Wagner, Dimitrios Laurin
Brunetti, Lorenzo
Jang, Albert
Baker, Matthew L.
Varadarajan, Navin
Hegde, Meenakshi
Kim, Yong-Mi
Heisterkamp, Nora
Abdel-Azim, Hisham
Ahmed, Nabil
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41375-020-0792-2
- URN
-
urn:nbn:de:101:1-2021020715340000029311
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:29 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Fousek, Kristen
- Watanabe, Junji
- Joseph, Sujith K.
- George, Ann
- An, Xingyue
- Byrd, Tiara T.
- Morris, Jessica S.
- Luong, Annie
- Martínez-Paniagua, Melisa A.
- Sanber, Khaled
- Navai, Shoba A.
- Gad, Ahmed Z.
- Salsman, Vita S.
- Mathew, Pretty R.
- Kim, Hye Na
- Wagner, Dimitrios Laurin
- Brunetti, Lorenzo
- Jang, Albert
- Baker, Matthew L.
- Varadarajan, Navin
- Hegde, Meenakshi
- Kim, Yong-Mi
- Heisterkamp, Nora
- Abdel-Azim, Hisham
- Ahmed, Nabil
- SpringerLink (Online service)
Other Objects (12)
Digital-droplet PCR for quantification of CD19-directed CAR T-cells
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Pharmacological control of CAR T-cells by dasatinib
Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies
Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant
Characterisation of tumour-intrinsic determinants and drug-induced modulation of response to CD19-CAR T-cells in nodal B-cell non-Hodgkin lymphomas
Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy – Moving Target for Industry?
Antigen glycosylation regulates efficacy of CAR T cells targeting CD19
Treatment of Systemic Lupus Erythematosus using BCMA-CD19 Compound CAR
Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T
CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
Digital-droplet PCR for quantification of CD19-directed CAR T-cells
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Pharmacological control of CAR T-cells by dasatinib
Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies
Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant
Characterisation of tumour-intrinsic determinants and drug-induced modulation of response to CD19-CAR T-cells in nodal B-cell non-Hodgkin lymphomas
Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy – Moving Target for Industry?
Antigen glycosylation regulates efficacy of CAR T cells targeting CD19
Treatment of Systemic Lupus Erythematosus using BCMA-CD19 Compound CAR
Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T
CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
Digital-droplet PCR for quantification of CD19-directed CAR T-cells
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Pharmacological control of CAR T-cells by dasatinib
Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies
Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant
Characterisation of tumour-intrinsic determinants and drug-induced modulation of response to CD19-CAR T-cells in nodal B-cell non-Hodgkin lymphomas
Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy – Moving Target for Industry?
Antigen glycosylation regulates efficacy of CAR T cells targeting CD19
Treatment of Systemic Lupus Erythematosus using BCMA-CD19 Compound CAR
Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T